MTN-043 is a Phase IIIb open-label trial under development that will evaluate whether the dapivirine ring and Truvada as daily PrEP are safe to use by women who are breastfeeding. The study, which will be conducted at trial sites in Malawi, Uganda, South Africa and Zimbabwe, will enroll up to 200 mothers and their breastfed babies. The MTN has already conducted a study (MTN-029/IPM 039) that involved U.S. women who were no longer nursing their babies but still producing milk, which found dapivirine was absorbed at very low concentrations in breastmilk.
See
A Time to Deliver: Preventing HIV in Pregnant and Breastfeeding Women
17-October-2018